As part of a broader plan to lower prescription drug costs, the Trump administration has proposed eliminating rebates in the Medicare Part D prescription drug coverage program, and passing any savings through to the consumer at the pharmacy counter.
This change could fundamentally alter how some biopharmaceutical companies talk about pricing and value. Though experts disagree on what the rule means for patient costs, one thing is clear: the President will want to show he has taken action to lower drug costs, particularly heading into the 2020 election.
This webinar will answer the following questions:
- What is the Rebate Rule and how will it affect the healthcare industry? Specifically, how will the rule change the dynamic between pharma and payers, both as it relates to formulary development and media scrutiny?
- What are the implications of the rule on value and pricing communications?
- What do biopharmaceutical companies need to do today to prepare? What do companies need to start thinking about long term?